SLC5A2 and chronic kidney disease: While ACEi, ARBs, and SGLT2 inhibitors target hemodynamicfactors and SGLT2 inhibitors, GLP1-RAs, and other antidiabetic therapies targetmetabolic factors, there are no treatments available to date that arespecifically designed to target inflammation andfibrosis.67,71, -73 Evidence suggests thatoveractivation of the mineralocorticoid receptor (MR) leads to inflammation andfibrosis in the kidneys and heart, where the MR is extensively expressed,resulting in progression of CKD and CV disease.74